Key points from article :
Available in their report: Risk-Benefit Analysis of Dasatinib + Quercetin as a Senolytic Therapy.
Dasatinib is a well-established medication used in the treatment of cancer.
Quercetin is a flavonoid common in plants.
They affect different types of senescent cells, they are often employed in combination.
Clearing senescent cells in rodents can prevent age-related diseases and extend the healthspan by up to 35%.
Screened over 3300 papers to find over 150 clinical and pre-clinical studies in its analysis.
Only results from 3 trials in humans in which D+Q was evaluated as a senolytic therapy.
Focussed on senescent cell markers - which are only hypothesized to translate to clinically meaningful effects.
2 of clinical studies were in patients with pre-existing disease - may not have an effect in healthy individuals.
The potential risks of D are extensive and well-known through its use in the treatment of cancer.
Prudent to avoid the use of D+Q as a senolytic therapy.
